

ABSTRACTS COLLECTION

ACNP 64th Annual Meeting: Keyword Index

© The Author(s), under exclusive licence to American College of Neuropsychopharmacology 2025

Neuropsychopharmacology (2026) 51:612–628; <https://doi.org/10.1038/s41386-025-02283-0>

Key Word	Submission Number(s)
(2R,6R)-hydroxynorketamine	P189, P264, P609
(R,S)-ketamine	P121, P230, P267, P533
[11C]CPPC	15.1
[18F] FEPPA	P253
17-β-estradiol	P4
1H MRS	P328, P330, P456
1H-MRS	P754
22q11 deletion syndrome	46, 46.2, 46.5, P458
22q11.2 deletion syndrome	46.3
31P Magnetic Resonance Spectroscopy	P527
3D genome	P871
5-HT ₂ Receptors	P359
5-HT _{2A} Agonist	P627
5-HT _{2A} receptor	45.4, P655, P664
5HT4R agonist	P64
5-MeO-DMT	P163, P666, P675
7 Tesla fMRI	31.4
7-hydroxymitragynine	P321
7q11.23 copy number variation	P488
ABCD	P6
ABCD study	P12, P13, P170, P516, P793
abstinence	26.4, P698
abstraction	P184
academic performance	P281
Accelerated intermittent theta burst stimulation (iTBS)	P233, P572, P581
Accelerated iTBS	27, P576
acetylcholine	P353, P479, P453, P637
Across Species	24
Actigraphy	P117
actin remodeling	P364
Action-outcome associations	P738
activated microglia	29.2
Active Avoidance	P206
Acute agitation	P148
Acute and Chronic Stress	P192, P307, P358, P843
Acute effects	P642
Acute Stress	P97, P202, P293, P510, P764, P834, P837, P842
Acute Traumatic Stress	4.3, P707
Acute treatment	14.4, P412
Adaptive Behavior	P65, P145
Adaptive deep brain stimulation	P568
Adaptive immunity	P91
Adaptive mechanism	48.5
Addiction	10, 19, 30, 11, 11.3, 20, 20.5, P433, P544, P723, P286, P380, P622
Addiction comorbidity	P732
Addiction phenotypes	P374, P378, P385, P629
Addiction-like behaviors	30.2, P374, P736
Addictions Neuroclinical Assessment	P308
Addictive behavior	43, P330
Addictive screen use	P554
Adeno-associated Virus	P820
ADHD	P115, P169, P170, P171, P490, P522, P576, P610, P816
adjunctive	P249
adjunctive treatment	P250
Adolescence	3.4, 28.4, P13, P63, P3, P6, P10, P11, P21, P22, P27, P48, P49, P106, P324, P344, P417, P494, P554, P576, P669, P824
Adolescence- Critical Period	36.4, P8, P29
Adolescent	P5, P60, P154, P409, P852
Adolescent Alcohol	P736
Adolescent Anxiety	56.4, 56.5, P8, P417
Adolescent Brain and Cognitive Development Study	P539
Adolescent Brain Cognitive Development study	22.1, P1, P493
adolescent cannabis	P386
Adolescent Depression	20, 20.2, 22.2, 22.3, 56.4, P2, P8, P9, P12, P200, P252, P254, P832
adolescent development	22, P7
Adolescent psychiatry	P661
Adolescent PTSD	39.3, P10, P695
Adolescent social isolation	P435, P831, P840
adolescent stress	48.2, P28, P844
Adolescents	P70, P169, P545
adult clincial anxiety	P439
adverse childhood experiences (ACE)	P539, P646
Adverse drug reaction	P430
adverse effects	P160
adverse event	P245
Adverse prenatal exposure	P22
Adversity	P721
affect	P177
Affect Regulation	13.2
affective components of pain	P416
affective disorders	57.1
affective disorders risk	P549
affective neuroscience	P218
age	P515
age of initiation	P419
Ageing	5
aggression	P31
Aggressive behavior	P32
Aging	54, P63
aging with schizophrenia	P156, P770
Aging; Cognition; Stress; Acetylcholinesterase; Splice Variants	P101, P801
AI	P34
Air Pollution	P417
Alcohol	3, 3.2, 10.3, 35, P97, P116, P285, P288, P291, P323, P326, P331, P333, P372, P391, P405, P729
Alcohol Abstinence	P462
Alcohol addiction	P357, P394

- Alcohol and substance use disorders P330, P332, P336, P340,
..... P342, P390, P433, P460, P553, P727
- Alcohol consumption 10.2, 44.4, P155, P393, P485, P716
- Alcohol dependence P142, P286
- alcohol drinking P285
- Alcohol intake P425
- Alcohol Response P300
- Alcohol Subjective Response P288, P303
- Alcohol Use Disorder 3.4, 35.5, P153, P311, P312, P334, P19,
..... P97, P294, P306, P308, P318, P337, P353, P392, P401,
..... P535, P537, P538, P565, P623
- Alcohol Use Disorder - Treatment P117, P158, P296, P297,
..... P310, P315, P328, P339, P355, P456, P485, P596
- Alcohol use disorder and drug addiction 3.5
- alcohol withdrawal P369, P370
- Alcoholic Liver Disease P99
- Alcohol-seeking behavior P346
- ALFF P537
- allopregnanolone P310
- allostatic load P332
- Allosteric Ligands P359
- Alpha-1A adrenoceptor P557
- Alpha-Adrenergic P557
- ALS P482
- alternative splicing 50.3
- altruism P823
- Alzheimer's Disease 13.2, P59, P609, 13, 13.3, 13.4, 13.5, 55,
..... 55.5, P278, P486, P481, 31.2, 55.4
- Alzheimer's dementia P485
- Ambiguity P206
- Ambulatory Assessment P278, P416
- American Indian P514
- AMPA receptors P189, P236, P679
- Amphetamine P556
- aMSM P530
- Amygdala 42.4, P591, P839, P5, P175, P256, P294, P475,
..... P532, P590, P645, P704, P710
- amygdala-based networks P586
- analgesia P621, P628
- Anandamide P425
- anhedonia 12, 12.1, 12.2, 12.4, 51, 51.2, P573, P172, P188,
..... P210, P220, P223, P258, P583, P616, P673, P719
- Animal Models 30, P629
- Animal models of addiction P357, P363, P399, P730, P732
- anorexia nervosa P409, P411, P413, P524, P412
- Anosmia 49.1
- Antagonist Ligands P610
- Anterior cingulate cortex P423, P863, 40.4, 43.3, P81, P241,
..... P454, P588, P621, P740
- Anterior Hypothalamic Nucleus P79
- anti-brain antibodies 29.2
- Anticholinergic medication burden P643
- Anticipatory reward activation P229, P554
- Antidepressant P204, P239, P267, P271, P659, P669, P675
- Antidepressants P82, P196, P208, P268
- Antifatigue P80
- Antigliadin antibodies (AGA IgG) P804
- Anti-inflammaory drugs P783
- Anti-inflammatory drugs P225
- antipsychotic P245, P249
- antipsychotic drug P607
- Antipsychotic drugs P812
- Antipsychotic induced weight gain P444
- Antipsychotic monotherapy P597
- Antipsychotic Polypharmacy P30
- Antipsychotic response P797
- Antipsychotic Treatment P603, P643
- antipsychotic-induced metabolic dysfunction P768
- Antipsychotic-naïve first-episode psychosis P597, P794
- Antipsychotic-naïve first-episode schizophrenia P751
- Antipsychotics P598, P617
- Anxiety P521
- Anxiety 13.5, 56, 56.5, P5, P55, P59, P60, P140, P222, P246,
..... P426, P427, P459, P555, P570, P586, P634, P772, P51
- Anxiety & PTSD P424, P440, P709
- Anxiety and Depression P58, P61, P207, P237, P532, 4.1
- Anxiety and stress P72, P200, P827
- Anxiety development P54
- anxiety model 41
- anxiety state P62
- Anxiety-related behaviors P668
- Anxiety-related circuitry P53
- Anxiety-related circuits 38.2
- anxiolytics P61
- APD-induced metabolic disease P812
- Appetite P225
- approach-avoidance conflict 38, 38.3, P172, P724
- apremilast P565
- APRO P423
- architecture P34
- Area prostriata 38.2
- Arousal P127, P72
- Arterial Spin Labeling P3
- arterial stiffness P106
- artificial intelligence 14, 44, P149, P38, P86, P312
- Artificial Intelligence, Analysis, NeuroScience, Clinical Neu-
roScience, Pharmacology 2, P39, P47, P151, P376
- ASD P174, P506
- ASL P540
- associative learning P366
- Astrocyte P434, P435, P438, P820
- astrocyte-enriched extracellular vesicles 36.3
- astrocyte-neuron interaction P142, P826
- astrocytes 30.1, P360
- astrocytes, neuroinflammation, T cells, chemokines 17.1
- ATAC-seq P131, P185
- Attachment 6.5
- Attention 56.3, P490, P853
- attentional bias P54
- Auditory hallucinations P168, P179, P791
- Auditory Mismatch Negativity P777
- Autism 55, P415, P496, P512, P531, P567, P606
- Autism & depression P235
- autism spectrum disorder 7.2, 20.3
- Autism Spectrum Disorder (ASD) P491, P492, P493, P500,
..... P502, P516
- Autism spectrum disorder, animal mmodel, cannabidivarin ... 29.2
- autism Spectrum Disorders 6, 6.2, 34.2, 55.2, P165, P516
- Autoantibody P560, P751
- Autobiographical 39.5
- autobiographical memory 39
- Autoimmune encephalitis P560
- autoimmunity 52, P564, P751
- Automated Facial Affect Recognition P33
- Automated natural speech analysis 14.1, P34, P45
- autonomic nervous system 20.4
- autophagy P192
- aversion 19.3, P71
- Aversive Learning 57.1, P475, P712
- Aversive Motivation P451
- avoidance P634
- Axon collaterals P464
- axons P144
- Basal Ganglia 8.4, 18.5, P468
- basolateral amygdala P81, P140, P580, P711, P842
- Bayesian Modeling P66

BBB changes	17.1	brain response to cannabis cue	P544
BDNF	P837, P840	Brain States	P304
bed nucleus of the stria terminalis	P392	brain stimulation	1.3
behavior	29, 29.5, P566, P68, 19.4	Brain Structure	28.3, P106, P597, P860
behavioral activation system	P543	brain transcriptomics	P609
Behavioral approach	P786	brain wiring	P648
behavioral approach system	P114	Brain-aging	5.4, P178
behavioral economics	P377	Brain-Based Predictive Modeling	12.3, 48.5, 53.1, P12
behavioral genetics	P726	brain-behaviour relationships	P536
Behavioral Health	P84	breast cancer	P164
behavioral inhibition system	P114	breast cancer chemotherapy	P439
behavioral mechanisms	14.3, P348	breastmilk	51.3
Behavioral Model	P502	brexanolone	P310, P696
Behavioral Pharmacology	P76, P625	Bulimia nervosa	P410, P408
Behavioral Phenotyping	P50, P506	buprenorphine	26.2, 23, 23.4, 26.5, 34.4, P290, P849
Belief Updating	P66	Buprenorphine-Naloxone	23.2
benzodiazepine	P677	CA1	P62
benzodiazepines	P486, P781	Caenorhabditis elegans	P74
big data	22	Calcineurin	21.4
Big Five Personality Factors	P327	calcium imaging	P62, P665
binge drinking	P565	Calcium signaling	21.4
Binge Eating	P414, P331	calcium-permeable AMPA receptors	6.5
Binge Eating Disorder	30, 30.2, 30.3	California mice	P841
Binge-eating disorder	P410	Callous-unemotional traits	P182, P548
Bioinformatics	36, 36.3, P199	CaMKII	21.4
biological rhythms	P269, P819	cAMP signalling	P605
Biology of aging	15	Cannabidiol	P155, P395, P400, P411, P428
Biomarker	16, 48, 48.2, P778, P84, P88, P89, P96, P104, P302, P704, P788, P792, P85, P332, P779, P856, P83, 36	cannabidiol (CBD)	P160
Biomarker Candidates	5.3, P82	cannabidiol (CBD), tetrahydrocannabinol (THC)	P429
Biomarker Prediction	2, P100, P538	cannabigerol	P642
Biomarkers for Risk Assessment	14.4, P122	cannabinoid	P109, P614, P642
Biopsy	49.3	cannabinoid receptor type 1	P16, P742
bipolar depression	23.3, P110	cannabinoids	P505, P602
bipolar disorder	32.2, P107, P114, P106, P108, P110, P111, P112, P116, P117, P118, P119, P120, P121, P123, P124, P125, P126, P127, P148, P173, P215, P236, P279, P529, P560, P744, P795, P819, P868, 25, 25.2, 25.3, 25.4, 27, 32, 32.1, 32.3, P810	Cannabis	P447, P109, P160, P301, P326, P341, P433, P437, P739, P742, P748
Bipolar Disorder risk	P122	cannabis abstinence	P325
Bipolar I Depression	P126	Cannabis edibles	P301
Bipolar I disorder	P115	cannabis use	P11, P325, P368
bipolar II disorder	51, 51.2, P227, P121	cannabis use disorder	P246, P302, P313, P314, P319, P327, P360
Birth Outcomes	P715	Cannabis Withdrawal	P698
Blood biomarker	P98	Cannabis-Tobacco Co-use	P306
Blood Pressure	P118	capsulotomy	P630
Blood-based biomarkers	P59, P91	Cardiac Autonomic Tone	P866
Blood-Brain-Barrier	10.5, 17, 17.3, 48.2, P108, P191, P394	Cardiometabolic Risk	P768
BNST	P827	Cardiovascular Disease	P120
body dysmorphic disorder	P518	cardiovascular function	P106
Body Mass Index	P118	Cardiovascular Physiology	20.4
BOLD fMRI signal	P182, P202, P293, P755	Cardiovascular Safety	47, 47.2
BOLD Signal Variability	P521, P531	Career Development	P281
Borderline Personality	P9	Caregiver Support Chatbot	P40
Borderline Personality Disorder	P649, P662	cariprazine	P287
Brain Anatomy	53.3	catalysis	P429
Brain and cardiovascular responses	P202	Catecholamine regulation	P76
Brain Based Markers for Depression	P87, P218, P264	Caudate	P409
Brain Circuits	35.4, 4	causal discovery analyses	P41
brain connectome	P393	Causal Modeling	22.4
Brain development	20.3, 24, P4, P8, P22, P324, P501, P534, P539, P546, P550, P741, P809	Causal Pathways	P49
brain glucose metabolism	P318	CB1 receptor	P617
Brain Insulin Resistance	P252	CBD	P411
brain iron	P171	CBT	P521
Brain organoids	P133, P189, P264, P497	CBT-I	P214
Brain plasticity	6, P665, P871	Celecoxib	P253
brain proteomics	P406	CELL TYPE SPECIFIC	P441
		cell types	P705
		Cell-type diversity	P461
		cell-type specific	P625
		Cellular metabolism	P192, P384
		Cellular senescence	15.2

central amygdala	P440, P612
Cerebellum	54, P166, P759, P796, P464, 54.2, 54.3, 54.4, 54.5
Cerebral Blood Flow	20.4, P3, P120, P540, P781, P805, P868
Cerebral Cortex	21
cerebrospinal fluid	P747
c-Fos	P381
CFTR modulators	P430
Channelopathy	P164
Chemobrain	P164
chemogenetics	21.2, P483, P623, P730
child and adolescent psychiatry	P47, P530
Child development	P424, P548
Childhood Adversity	P418
childhood anxiety	P57
childhood maltreatment	P17
Childhood maltreatment exposure	48.4
childhood psychiatric symptoms	7.3
Childhood trauma	7.1, 36.4, 39.3, P16, P295, P537, P688, P708
Children and Adolescents	22.2, P4, P53, P280
ChIP-sequencing	P24
Choline	P504
cholinergic function	P77
Cholinergic system	P135
Chronic adolescence stress	P14
chronic alcohol	P370
chronic pain	5.2, 43.2, P315, P329, P428, P612, P640, P740
chronic pain treatment	P426
chronic pain, inflammation, biomarker	P602
Chronic social and non-social stress	P101
chronic social defeat stress	P845
Chronic social stress	3, 3.2, P21, P272, P277, P343, P724, P846
Chronic unpredictable mild stress	P270, P725
Chronic variable stress	P847
chrono-pharmacology	25.4
cigarette smoking	P293, P581
circadian	P379, P734
circadian rhythm	25.4, 27.4
Circadian rhythms	P817, P282, P390
Circuit Development	29.4
Circuit dissection	54.4
circuit optogenetics	P737
Circuit-function	P457
circular RNA	P82
Circulating cell-free mitochondrial DNA	P205
claustrum	43, 43.1, 43.2, 43.3, 43.4
click-chemistry	P429
clinical course	32, 32.1
clinical efficacy	51.1, P780, P802
Clinical heterogeneity	P789
Clinical high risk state for psychosis	P749
clinical high-risk for psychosis	P805, P42, P96, P761, P777, P781
Clinical interventions	P58
Clinical Neurobiology	P631
Clinical NeuroScience	P200
clinical outcome assessments	P790
clinical outcome prediction	P760
Clinical practice	P698
Clinical psychiatry	P631
clinical psychopharmacology	25
Clinical Subtypes	P704
Clinical trial	16, 30, 42, P159, P194, P584, P660, P780
clinical trials	P706
clinical trials methodology	P790
clozapine	P600, P800, P746
clozapine response	P758
CNS Clinical Trials	P162, P230, P601, P657
CNS drugs	P482, P595
CNS Radiotracer	P557
cocaine	P335, P341, P358, P361, P365, P366, P387, P403, P414, P723
cocaine addiction	P406
cocaine reinstatement and taking	P399
cocaine self-administration	50.2, P359, P384, P396, P728
cocaine self-administration and reinstatement	P381
Cocaine sensitivity	P728
cocaine use disorder	1.4, P186, P295
cocaine, nicotine, sex differences	P399
Cognition	5, 22.1, 27.4, 54, 54.4, P2, P88, P100, P166, P173, P175, P380, P428, P493, P622, P647, P648, P792, P869, P114, P325, P614, P779
cognitive	P58
Cognitive / behavioral flexibility	54.4, P235, P386, P678, P737
cognitive aging	P507
cognitive assessment	P45
Cognitive biomarkers	P102
cognitive control	P682
cognitive control network	P168, P183
Cognitive deficits	P504
Cognitive effort	P167, P408
cognitive flexibility	11.2, 54.5, P396
cognitive function	54.2
Cognitive Functioning	P207, P632, P646, P801
Cognitive impairment associated with schizophrenia	45.5, 55.3, P45, P742, P770, P776, P780, P788, P806, P811, P813
Cognitive impairments	40.3, 42.2, P604
Cognitive Neuroscience	P295
cognitive reappraisal	P570
cognitive remediation	P164
Cognitive Resilience	15.3
Cogstate Battery	P242
colony stimulating factor 1 receptor	15.1
Combat PTSD	P456, P695
Community Engaged Research	9
Community health center	P204
Comorbidity	P401
Comparative effectiveness	P862
Complement 4	P808
Complement C4	28, 28.2, 28.5
Complement component 4	28.3, 28.4
complement pathway	P85
Compulsive behavior	P380, P668
compulsive drug intake	3
Compulsive eating	30.4
Compulsivity	P489, P744
Computational Cognitive Neuroscience	57.2, P181, P184, P408
Computational Methods	P182
computational modeling	57.1, 57.3, P75, P187, P756, P822, 36.5
Computational Modelling of Neuroimaging	P181
computational models of decision-making	P221, P322
Computational Neuroscience	39.4, P179
computational psychiatry	14, 14.1, 57, 57.4, P177, P180, P232, P775, P822
Computational Reinforcement Learning Model	P184, P729
concussion	P51
conditioned place preference	P352, P354, P365, P414
Conditioning Place Preference	P363, P383
connectivity	P765
connectome	35.5
connectomics	26.4, P183
Context	P451, P621
contextual fear	P25
coordinated specialty care	P750
coping	P480, P870
Coproduction	9
copy number variation	46.3
Correlation	25.3

Cortical Development	7.4	 P196, P197, P198, P203, P204, P205, P210, P214, P215,
cortical dynamics	45.2	 P221, P222, P234, P238, P243, P251, P253, P257, P258,
Cortical excitability	P852	 P259, P261, P266, P270, P272, P275, P276, P277, P334,
cortical GABA and glutamate	P863	 P439, P469, P508, P540, P555, P580, P594, P718,
Cortical GABA neurons	21.1	 P720, P761, P817, P846, P862, P865, P11, P188, 31.3
Cortical Hierarchy	P552	Depression and Anxiety
Cortical networks maturation	P554	Depression Inflammation Cytokine
cortical plasticity	45.2	Depression model
Cortical pruning	28	Depression risk
cortical thickness	17.2, 22.1, P22	depression schema
Corticosterone response to stress	P838	Depression subtypes
Corticostriatal circuit	30.4, P179, P480	Depressive Mood
Cortico-striatal-thalamo-cortical Circuits	38, P519	depressive symptoms
Corticotropin-releasing factor (CRF)	P339, P465	desvenlafaxine
Corticotropin-Releasing Hormone	29.3, P838	deutetrabenazine
Cortisol	P650	Developmental Programming
Cortisol response to stress	P54, P785	Developmental Psychopathology
COVID-19	P161, P243	Developmental trajectory
craving	26.4, P150, P544, P640	Dexmedetomidine
C-reactive protein	P633, P103	Diagnostic Categories
CRF1 Receptor Antagonist	P707	Diagnostic specificity
CRISPR/Cas9	P503	diffusion MRI
CROSS DISORDERS	P136	Diffusion Tensor Imaging (DTI)
Cross-cultural	P632	diffusion tractography
cross-species	48	Diffusion Weighted Imaging
cross-species research	45	diffusion-weighted magnetic resonance imaging
CRP	P173, P787	digital assessment
CSF	P551	Digital Biomarkers
CSF Biomarkers	55.4, P102	Digital Medicine
cTBS	P188	Digital phenotyping
Cue Reactivity	11.5, P293, P297, P640, P647	digital psychiatry
cue-induced craving	P647	digital sensing
cue-induced-reinstatement	P387, P450	digital therapeutics
cue-reactivity	1.4, P176	dimensional
Culture,	P644	Dimensional outcomes
cyclic AMP	P402	dimensions of psychosis
CYP2D6	P766	Direct pathway
cytokine	P142	discontinuation
cytokines	P565, P690, P747	Discrimination
D1 dopamine receptors	18.2, 26.3, P556, P637	Disease risk prediction
D1-D2 dopamine receptor heteromer	P270	disinhibition
D2 dopamine receptor	P812	Disrupted-in-Schizophrenia 1
daily stressors	P850	disruptive behavior disorders
Data Quality Monitoring	P149	Dissociation
DBS	P755	Distress intolerance
Decision Making	11.2, P81, P511, P618, P829, P81, P511,	dmPFC
.....	P618, P829	DNA damage response
Decision tree	P239	DNA double strand breaks
decision-making	P167, P177	DNA Methylation
decision-making	P718	DNA:RNA hybrid R-loop structure
Dectin-1	P143	dopamine
Deep Brain Stimulation	27.1, P579	 12, 19, P719, P65, P127, P144, P179, P243, P347,
Deep learning	P50, P491, P526, 14.2	 P349, P358, P366, P389, P457, P463, P470, P480, P509,
default mode network	P592	 P513, P522, P535, P556, P617, P625, P637, P678, P731,
Default mode network (DMN)	P713	 P737, P836, 8, 8.3, 11, 11.3, 12.2, 19.2, 19.4, 26, 26.3, 38.1, 54
delta9-tetrahydrocannabinol	P428	Dopamine (D2, D3) receptors
delta-9-tetrahydrocannabinol	P368	Dopamine and Serotonine
delta9-tetrahydrocannabinol (THC)	P160	Dopamine circuits
delta9-tetrahydrocannabinol, cannabidiol	P426	Dopamine D4 receptor
Dementia	P484, P643	Dopamine receptors
Dementia Caregiving	P40	Dopamine, Acetylcholine
Dementia-related psychosis	P39	Dorsal Attention Network
Dendritic fields	P464	dorsal raphe
Dendritic Spine	P840	Dorsal raphe nucleus
dense sampling fMRI	11.4	Dorsal striatum
dentate gyrus	P178, P466	dorsolateral prefrontal cortex
Depression ... 12.1, 12.2, 12.4, 23.3, 27.1, 27.3, 47.3, 48.5, 56, 56.2,		dorsolateral prefrontal cortex (DLPFC)
..... P55, P89, P91, P95, P101, P147, P150, P173, P189, P192,		dorsolateral striatum
		Dorsomedial striatum

- drift diffusion model P186, P221
 Drift-Diffusion Modelling P169
 drug addiction 40.3, 43.3
 drug cue reactivity P287
 Drug Discovery - new approaches P50, P105, P482, P500, P595, P599
 drug discovery/development P339, P617
 Drug metabolism P141
 drug Relapse P361, P382
 Drug repurposing 10, 10.3, P382
 drug seeking P293, P347, P361, P395
 drug self-administration P513
 drug side effects P803
 drug target P357, P605
 Dual Diagnosis P117
 Dual Orexin Receptor Antagonists 30.2
 durability of benefit P260
 Duration of Untreated Psychosis P794
 dynamic causal modeling P861
 dynamic modeling 14.3
 Dynamical Systems P857
 Dynamical system model P75
 Dynamics 20.2, 56.3
 Dynorphin 18.4, P460, P612
 Dysfunctional beliefs P762
 Dysphoria 30.3
 E/I balance P814
 E/I imbalance 46.2
 Early auditory information processing 46.2
 early brain development 7.3
 Early identification of risk 27.2, P529
 Early life adversity, 7.3, P26
 Early life stress 48.3, P18, P19, P20, 29.4, 48.2, P27, P29, P137, P825
 early life unpredictability P172
 Early Phase Drug Development P616
 early psychosis P492, P542, P639, P648, P748, P750, P765
 Early Trauma 48
 early-life adversity 29.3, P24, P352, P435
 Early-life stress/adversity P15, P17, P28, P831, P832
 Eating behavior P517, P863
 Eating disorders 30, P409, P411, P413, P511, P678
 E-Cigarette P344
 EcoHIV P143
 ecological momentary assessment 11.4, P9, P41, P697, P851, P857, P858
 Education and Training P37, P593
 EEG 1.3, 21, 57.2, P164, P174, P477, P482, P487, P491, P663, P746, P778, P779
 EEG biomarkers 1, 45.2, 45.5, P35, P86, P92, P157, P582, P641, P815
 EEG biomarkers and target engagement 45, 55.3, P235, P495, P582
 EEG connectivity P87, P572
 EEG synchronization 21.3
 EEG/ERP electrophysiology 1.4, 45.5, P56, P211, P490
 EEG-fMRI P317, P449
 effectiveness P854
 efficacy P757
 effort sensitivity 57.4
 e-field modeling P571
 egocentric representation P454
 electroconvulsive therapy P261, P268, P575, P755, P862
 Electroencephalography (EEG) 46, 46.2, P44, P194, P254, P262, P573
 Electronic cigarette (e-cigarette) P70
 electronic health record (EHR) P126, P341, P643
 electrophysiology 13.5, P622, P736
 ELISA P560
 EMA P415
 emergence P734
 Emerging Therapies P661
 emotion P234, P821
 Emotion Conflict Task P410
 emotion processing 56.4
 emotion regulation 11.5, P246, P415, P419, P410
 Emotional dysregulation P21, P418, P870
 emotional memory P663
 Emotional Pain P703
 emotional processing P5, P420
 Emotional regulation P56, P175
 Empathy P548
 emulated target trial P484
 endocannabinoid system 34, 34.2, P52, P16, P358, P400, P405, P596
 Endocannabinoids 19.2, P123, P424, P425, P427, P455, P463, P617, P645, P830
 endogenous opioids P421, P455
 endophenotypes P726
 endothelial cell pathology 17.1
 endotoxin P147, P311
 Endpoint Reliability P38
 Endurance P80
 Energy P225
 energy metabolism P119, P754
 Energy metabolism. P412
 Engineered EVs 36.2
 engram P78
 enkephalin P71, P421
 enriched environment P349
 Entorhinal-hippocampal circuitry P453
 Environmental exposures P278, P490
 Epigenetic P98
 Epigenetic Aging 48.4, P17
 Epigenetic Modification P24
 Epigenetic regulation 4
 Epigenetics 48.3, P20, P137, P141, P190, P277, P284, P450, P715, P871
 P427, P624
 epilepsy P663, P799
 episodic memory 9
 Epistemic Justice P277
 Epitranscriptomics 40, P779
 ERP 40.5
 ERPs P632
 Error-monitoring 38.2
 Escape behavior 33, P407, P559, P604
 Esketamine P223, P263
 Esketamine nasal spray P578
 Essential Tremor 4.4, 4.2, P365, P439
 estradiol 4
 Estrogen P73
 estrogen receptor 4.2, P513
 estrogen receptor beta 4.3
 estrogen receptors P365
 estrous cycle P419
 ethinyl estradiol P777
 event-related oscillations P771
 everyday functioning 6.2, 46.3
 excitation-inhibition balance P688, P813
 excitatory / inhibitory balance 29.4, P809
 Excitatory Synapses 20.2, 20.3, P19, P530, P535
 executive function P682
 executive network P24, P837
 exercise P190
 Exosomes

Expectancy	P298	Frontoparietal Network	P289
experience sampling methodology	44.3	frontostriatal circuitry	P583
explore-exploit dilemma	11.2, P180	Fronto-striatal circuits	P648
Exposure therapy	P543, P693	frustration	P589
extended amygdala	3	Frustrative nonreward	P423
Extended-release naltrexone	23.2	Functional anisotropy	27.1
Externalizing behavior	P283, P49	functional brain connectivity	54.3, P232
Extinction	P452, P693	functional brain networks	P528
Extinction learning	P625	functional genomics	P807
extracellular matrix	P360	functional magnetic resonance imaging	P833
Extracellular vesicles	36, 36.2, 36.4, 36.5, P563	functional magnetic resonance spectroscopy	P688
eye-tracking	P174	functional MRI	27.1
F-18 PET Imaging	P39, P559	Functional MRI (fMRI)	31.4, 40, 54.5, P53, P168, P176, P184, P214, P218, P295, P304, P403, P425, P496, P517, P518, P519, P532, P549, P588, P651, P683, P764
FAAH	P455	functional neuroimaging	12.3, P319, P580, P584, P687
face expression synchrony	P821	functional outcomes	P762
face perception	P586	G protein coupled receptors	P138
Facial emotion processing	P5, P336	GABA	19, 19.2, 37.4, 42.2, P356, P505, P713, P847
family history	32.1	GABA and Glutamate	P629
Fast-acting Antidepressant	P619	GABA MRS	P300
fatigue	P207, P225	GABA receptors	P805
Fatty Acid Amide Hydrolase	P52	GABA transmission	19.5
Fear	P703	GABAA receptor positive allosteric modulator	P50, P262
Fear conditioning	36.4, 39.2, P78, P681, P691, P712, P711	GABA-A receptors	P267
Fear conditioning and extinction	39, 39.3, 42.4, P417, P625, P634, P680, P710, P699	GABAergic interneurons	P458, P623, P671, P709
Fear extinction	P424	GAD	P61
fear generalization	P63, P465	galanin	P354
Fear learning	P449, P842	gambling disorder	P330
fear memory	P449	gamified cognitive tasks	57.3
Fear renewal	P681	gamma oscillations	P187
female-specific vulnerability	P364	gamma power	P93
Fentanyl	19.3, P351, P383, P402, P608, P667, P367	gene expression	P141, P224
Fentanyl self-administration	P404, P376, P398, P436	Gene regulation	4.1
Fentanyl withdrawal	P373, P374	gene transcription	P265, P362
FGF-21	P509	General Linear Modeling	P680
Fgf-R1	3.5	Generalized Anxiety Disorder	P149, P61, P151, P543, P657
fiber photometry	P347	Generative Artificial Intelligence	P37, P46, P281
fine mapping	P337	Genetic biomarker	P208
firing rate	P615	Genetic High Risk Psychosis	46.2
first episode psychosis	P771	genetic mouse model	19.4, P487, P815
first-episode psychosis	P154, P747, P776, P805	Genetic Risk	P49
FKBP5	P140	Genetic Testing	P247
Flanker Task	P157	Genetic variability	P385
fluoxetine	P271	genetics	P694, P728
fMRI	12.1, 37.4, 39.2, 40.5, P171, P224, P302, P531, P534, P536, P538, P544, P551, P634, P640, P685, P748, P823	Genetics of depression	P265
fMRI biomarkers	P855	genome wide association study	P413
fMRI Connectivity	40.2	Genomic	P185
fMRI Effective Connectivity	P336	Genomics	P132, P413, P705
fMRI Functional Connectivity	54.5, P784	geriatric depression	P199, P213
fMRI Replication	P122, P313	Gestational stress	P717
fMRI, anxiety, threat	P57	ghrelin receptor	P297
fMRI-guided targeting	P584, P233	GHSR	P297
focused ultrasound	P329, P532, P580, P591	Globus Pallidus	P405
foetus brain	P835	GLP1	P285
Food Addiction	30.4	GLP-1	10, 10.3
food effect	P767	GLP-1 receptor agonist	10.2, 10.4, 10.5, P95, P237, P318, P323, P340, P618
Food Insecurity	P21	glucocorticoid receptor	29.3
food intake	P472	Glucocorticoids	P672
food reward	P229, P734	Glucose Metabolism	P598
Forensic psychiatry	P30	GluN2D	P619
formal thought disorder	P36	Glutamate	19, P356, P794, P797
fractional anisotropy	P542	Glutamate and GABA	P547
fragile X syndrome	P495	Glutamate homeostasis	30.4
Free water imaging	P492, P524	glutamate transporter (EAAT2)	P826
free-water	P542	Glutamatergic neurons	P79
Frontal Connectivity	P32	glutamatergic transmission	19.5, 46.5
frontocingulate circuit	P93		

Glutamine	P547	Human hippocampus	P867
Gluten-Free Diet	P804	Human Neuroimaging	5.3, 7, 20, 20.2, 20.5, 39, 39.3, 56,
Glycolysis	P846		56.4, 56.5, P2, P35, P240, P299, P420, P424,
glymphatic system	P438		P493, P546, P553, P804, P867
Glyph Allopregnanolone	P242	Hymenaea courbaril	P80
GlyphAllo	P242	Hyperactivity	P744
goal-directed behaviors	30.1, P474	hyperalgesia	P374
goal-directed control	P176	hyperscanning	P864
Gonadal Hormones	P393, P440, P499	Hypofrontality	P146
GPCR	35.3, P605, P664	hypothalamic-pituitary-adrenal axis	P832
G-proteins	19.5	hypothalamus	P510, P839
GPS	P299	IAPS	P764
GReX	P355	ibogaine	45.4
GrimAge acceleration	P701	IGF-1	P503
GRIN2D	P619	IL-1b	P562
Gut Microbiome	42.3, P856	IL-1R1	P562
Gut-Brain Axis	P845	Imaging genomics	P442
GWAS	P283, P355, P367, P441, P442, P444, P498, P728	Imaging-genetics	P170
habenula	35, 35.2, 35.3, 35.4	Immediate early genes	3.3
habit	P448	Immune Biomarkers	5, 5.3, 17, P832, P859
Habitual decision-making	P176	immune cells	17.1
hallucinations	P775	immune function	P690
HAM-A	P151	immune mechanisms	P195
harm reduction	P160	immune phenotype	P28
Health Equity	P706, P715	Immunity, neurodevelopment & aging	15.3
Health services	P204	Immunometabolism	P225, P787
Healthcare System Change	P125	immunopsychiatry	P91, P103, P783
health-related quality of life	P55	immunotherapy	52
Healthy controls	P519	Implicit association test	P221
healthy volunteers	P92	Impulsive behavior	P649
Heart rate variability	P90, P415, P700	impulsivity	53.1, P13, P69, P241, P150, P180, P186, P474
Heartbeat Evoked Potential	P866	in utero SSRI exposure	P216
Hegemonies	P644	In vitro	P608
Heroin	P730	in vivo calcium imaging	P25, P366, P725
heroin choice	P345	in vivo electrophysiology	P843, P476
heroin seeking	P722	In vivo fiber photometry	P77, P735
heterogeneity	P303, P531	In vivo Imaging	P178
Hi-C chromatin conformation	P807	incentive motivation	P451
High Density Sleep EEG	55.4, P815	Incubation of craving	P404
high fat diet	P67, P467	Incubation of drug craving	1, 1.1, 1.2, 1.3, 1.4, 43.4, P403
High fat diet induced obesity	30.1	incubation of oxycodone craving	P388
high-risk	P549	Independent Component Analysis	P759
Hippocampus	39.5	individual differences	P392, P398, P506
hippocampal connectivity	P23	individual variability	P760
Hippocampal Function	P24	Induced neurons	P808
Hippocampal neurogenesis	P131, P268	induced pluripotent stem cells	46
Hippocampal-prefrontal	P458	Induced pluripotent stem cells (iPSCs)	32, 46.5, P133, P134,
Hippocampus	4.1, 4.4, 37.2, P261, P268, P271, P394, P454,		P189, P497
.....	P459, P466, P506, P609, P708, P814, P840, P841	Infant fMRI	P498, P548
hippocampus subfields	P497	infant neuroimaging	7.2
Histone acetylation	4.2, P717	infection	P566
Histone methylation	P277	Inflammation	48.4, P804, 17, 17.2, 49.3, P108, P334, P29, P88,
HiTOP	57.3		P103, P158, P210, P254, P258, P307, P633, P719
HIV	50, 50.1, P18, P690	Inflammation and cytokines	P85, P97, P286, P311
HIV and Inflammation	P400	infralimbic cortex	P452
HIV associated neurocognitive disorder	50.3	Inhibitory control	P186, P408, P688
HIV-Associated Neurocognitive Disorder	50.4	Inhibitory interneuron signaling	P466
Homeostasis	P192	Inhibitory interneurons	P421
homeostatic plasticity	46.5	inhibitory neurons	21.3
hormonal contraceptive use	P419, P736, P870	Innate defensive behavior	P79
hormone manipulation	P224	insomnia	P214, P248, P290, P818
Hormones	P699	insomnia disorder	P818
hospitalization risk	10.4	Insula Connectivity	P550
hostility	P872	insula cortex	P550, P825
HPA axis	P510	Insula,	P90
human and non-human primates	P129	insular cortex	P294, P472
Human Clinical trial	P231, P317	insulin	P812
Human Genetics	P285, P445, P500	insulin resistance	P258, P507

integration of GWAS with brain omics	P185	Lipid metabolism	P258, P273
integrative neuroscience	P199	Lipidomics	P59
Intellectual disability	P491	lipocalin-2	P566
Interactomes	P136	Lipopolysaccharide	36.3
interbrain synchrony	P864	Lithium	P624
Interdisciplinary	P420	Lived Experience	9
Interferon Response Factors	P103	local field potentials	27.1, P487
intergenerational neuroimaging	P520	local gyrification index	P542
Intergenerational Transmission	7.1, P17, P831	locomotor activity	P282, P283
Intergenerational transmission of trauma	39.3	Locus coeruleus	13.4
internal capsule	P630	Locus coeruleus	13.5, P72, P464, P774, P615
Internal state modulation	38.2, P74, P668	Locus coeruleus (LC)	13.3
internalizing disorders	P56	loneliness	P280, P798, P822
interneurons	P422	long noncoding RNA	P145, P294
interoception	P147	Long-acting antipsychotics	P636
Interpeduncular nucleus	35.5	long-acting injectable	P636
interpersonal violence	P697	Long-acting injectable antipsychotics	P789, P803
interval timing	P166	long-COVID	P161
interventions	P427	longitudinal analysis	44.3, 57, P43
Intracellular Signaling	P664	longitudinal change	P544
intralaminar thalamus	P396	longitudinal imaging	P536
Intravenous self-administration	P407	longitudinal multimodal imaging	P309
intrinsic connectivity (fMRI)	P550	longitudinal studies	P215
ion channel	P616	longitudinal study	P102
Ion channels	25.3	Long-non-coding RNA	P276
iPSC	46.4	long-range chromatin interaction	P145
iPSC-derived neurons	32.3, P123, P338	long-term	P244
irritability	44.2, P423, P589	long-term results	P660
Irritability/Aggression	P855	Low Intensity Focused Ultrasound	P578
isolation	P841	Low-dose methotrexate	P783
iTBS	P576	LSD	P657
IV ketamine	P89, P93, P561, P684, P720, P854, P862	LSD microdosing	47.2, 47.3
IV- Ketamine	P173, P215	lumateperone	P219, P244, P245, P249
kappa opioid receptor	18.4, 26.5, 45.4, P612, P649	M1 and M4 Muscarinic Receptors	P637
Kappa Opioid Receptor Antagonist	34.4	M1 Muscarinic Receptors	P763
KCC2	P813	M4 muscarinic acetylcholine receptor (mAChR)	P159
Ketamine	23.3, 31, P222, P83, P194, P197, P540, P558, P604, P849, 31.3, 33	machine learning	5.2, 14.4, 44, 44.2, 53.1, P98, P477, P7, P12, P44, P45, P47, P170, P230, P398, P793
Ketogenic diet	25.2, P67, P300, P328, P412, P484	Machine Learning Classification	P68, P33, P39, P48
ketone monoester	P328	Machine learning clustering	P35, P788
kratom	P321	Macrophage	17.2
Kynurenic acid	P504, P561	macrophages	17.1
Kynurenine	P504	MADRS	P37, P151, P263
kynurenine pathway	P505, P561	Magnetic Resonance Imaging	27.4
L1 retrotransposons	P721	magnetic resonance spectroscopy	P107
Lactate	P83	magnetic resonance spectroscopy (MRS)	P797, P547
lactate shuttle	P645	magnetoencephalography	P93, P195, P212, P232, P776, P861
Lamotrigine	25.2	maintenance treatment	26.4
Language	56.3, 56.5, P652, P752	Major depression	12, 36.2, P246, P585, P849, P859, P230
Large Language Models	14.2, 44.2, P36, P40, P42, P46, P638	Major Depression Disorder	P20, P33, P226, P263, P533, P543
Large Scale Networks	20.2	Major Depressive Disorder	P191, P236, P239, P292, P587, P244, P245, P249, P260, P601, 27, 36.3, 47, 47.2, P208, P274, P575, P35, P86, P131, P163, P201, P219, P231, P233, P247, P248, P250, P256, P529, P547, P588, P662, P850
Late Life Depression	P202	major psychiatric disorders	P646
Late-life Depression	P262	maladaptive avoidance	57.1, 57.4
latent profile analysis	P31, P114, P848	mania	P107
latent states	P838	mania biomarker	27.2, P122
Lateral Habenula	P369, P370, P469	manic symptoms	P112
Lateral hypothalamus	P27, P820	marmoset	P274
Lateral Septum	P129	massage	P90
Lay Community Health Workers	P644	maternal behavior	P73, P717
LC	P551	maternal brain	P317, P864
learning and memory	45.3, P325	maternal care	6.4
learning generalization	P184	Maternal Depression	P224
Learning Health Network	P125	maternal functioning	51.3
lemborexant	P818	maternal sensitivity	P700
Leptin	P472		
life stress	P851		
Lifespan	20.3, 54.3		
limbic system	P843		

- maternal stress 6.4
 Matrix Metalloproteinase-9 (MMP-9) P844
 Matrix Metalloproteinases P360
 MDD P44
 MDD, PTSD P708
 MDMA 6.2, 34.3, P456, P651, P666, P693, P828
 measurement-based care P112
 mebufotenin P227, P228
 mechanism-based biomarkers 2
 mechanism-based phenotyping 57.4
 mechanisms 41
 MeCP2 P487
 medial habenula 35.5
 Medial Prefrontal Cortex 38.3, 38.4, P165, P358, P391, P421, P465
 Medial Prefrontal Cortex (mPFC) 6.3, 49.2, P14, P78, P146, P362, P381, P460, P470, P480, P568, P709, P811, P834
 Medication adherence P780, P786
 medications P290
 mediodorsal nucleus of the thalamus P681
 Medium Spiny Neuron P139
 Medium spiny neurons 8, 18.3
 MEG 56.2
 Memory 4.3, 31.2, 39.5, P447
 Memory and Learning P68, P74, P453, P506
 memory engram cell P361
 Mendelian Randomization P124, P285, P442
 menopause 37.4, 37.5
 Menopause, Mood, Childhood Stress, Neuroendocrinology, Women's Health, Sex Differences 37.2
 Menstrual Cycle P865, P866, P867
 Mental Disorders P104
 Mental Health P432, P824
 Mental health outcomes 22, 22.4, P204, P553
 mental illness P595
 Mentalizing 56.3, P567
 meta-analysis P111, P130, P198, P251, P549, P596
 metabolic P222
 metabolic function P88
 Metabolic Psychiatry 25.2, P408, P413, P768, P812
 Metabolic side effects P248, P598
 metabolism P484, P485, P748
 metabolomics 42.3
 Metabolomics signature P89
 metabotropic glutamate receptor P709
 metabotropic glutamate receptor 5 (mGluR5) P606, P825
 Metaplasticity P655
 metformin P341
 Methadone 26.5, P602, 26.2
 Methamphetamine 1.3, P146, P150, P351
 Methamphetamine use disorder 1.4, P322, P352
 methylone P162
 Methylphenidate P552
 mGlu5 5.5
 mGluR2/3 negative allosteric modulator P194
 mice P146, P80
 microbiome P348, P845
 microcircuit processing P461
 Microdosing with psychedelics 47, 47.1, 47.4, P670
 microglia 15, 15.1, 15.2, 15.3, 29.4, 29.5, P373, P435, P436, P437, P563, P564, P747, P343
 microglia and neurons 28.5
 microglia-neuron interactions 29, 29.3
 MicroRNA P265, P284, P342
 microRNAs 46.5
 microstructural imaging P758
 midbrain P462, P795
 Mild Traumatic Brain Injury 31
 Mindfulness Meditation P573, P682
 miRNAs 36, 36.3
 Mitochondria 46, P18, P190, P276, P384, P841, P846
 Mitochondrial DNA P119
 Mitochondrial dynamics P388
 mitochondrial dysfunction P205, P375, P120
 mitragynine P321
 mitragynine pseudoindoxyl P321
 Mixture modelling P714
 mobile sensing P279
 Modifiable Risk Factors P278
 Molecular imaging P508
 molecular mechanisms 50.4, 25.3, P224, P338, P190
 Molecular neuropathology P130
 Molecular Pharmacology P138, P664
 monetary incentive delay task P229
 Monetary reward P220, P229
 mood and anxiety disorders P66, P207
 Mood and Cognition P108
 mood disorder 27.4
 mood disorders 32.2, 33, P88, P212, P332, P819
 mood induction 56.2
 morphine P414
 Morphine sensitivity P67
 mother-child dyad P520
 mother-child dyads P864
 mother-infant interaction 51.3
 motivated behaviors 8.3, 43.1
 motivation P2, P210, P364, P719, P723, P731, P734, P738
 motor function P99
 motor learning P656, P658
 motor stereotypies P446
 mouse P503
 mouse brain P741
 Mouse model 25.3, P814, 53, P392, P624, P847
 movement disorders P523
 mPFC P276
 MRI 27, 53.3, P111, P236, P492
 mRNA P795
 mRNA translation 31.2
 MR-PET P635
 Mu opioid receptor 18.2, 19.5, 26, 26.3, 35.4, 26.2, P139, P284, P321, P354, 8.3, P628
 mulocclusion P816
 multimodal P542
 multimodal biomarkers 36.5
 multimodal data P1
 Multimodal imaging P183
 Multimodal Neuroimaging 53.2, P12, P514, P781, 37, P805
 Multimodality neuroimaging 50.2, 50.4
 Multiomics P195
 Multivariate analysis P599, P760
 multivariate data fusion P171
 multivariate pattern analysis P518, P538
 mu-opioid receptor agonist 34.4
 muscarinic M1 P811
 MVPA 39.4
 Mycobiome P143
 myelin P51
 Myelination P501
 myo-inositol P797
 N-acetylcysteine P154
 NAD+ P161
 naltrexone P345
 Native American populations P848
 natural language processing (NLP) 14.1, P43, P96, P798
 Natural rewards 19.3

Naturalistic Paradigms	56, 56.2, 56.4, 56.5, P304
Negative Affect	P322, P772
negative allosteric modulator	P372
negative emotionality	P19, P308
negative reinforcement	P463, P735
Negative Symptoms	49.3, P156, P639, P762, P787, P761, P782
Negative urgency	P852
Neighborhood Socioeconomic Deprivation	P240
neocortex	21.3
neonates	7.4
network neuroscience	P791
Network-Analysis	28.5, P302, P703
Neural activation	P14
neural circuitry	P733
Neural circuit and animal behavior	P393
neural circuits	6, 6.2, P511, P709
Neural decoding	P62, P449, P477, P851
Neural flexibility	P521
Neural mechanism	P685
Neural networks	48.5
neural oscillations	P577, P718
Neural Plasticity	P867
neural progenitor cells	P265
Neural Reward Circuitry	12.3, 40.4, P77
neuritogenesis	P594
neurobiological subtypes	17.3
neurobiology, stress, depression, anxiety	P273
neurocircuit mechanisms of addiction	18.5, 50.4
Neurocircuitry	P651
Neurocircuits	1.2, P477
Neurocognitive assessment	P15
neurocognitive function	P113
neurodegeneration	15, 15.2, P85
Neurodegenerative Disease	31, P136
Neurodegenerative disorders	31.5
neurodegeneration	31.3, P375
neurodevelopment	29, 53.1, 28, P563, P622
Neurodevelopmental and psychiatric disorders	P490
Neurodevelopmental Disorders	P488, P499, P526, 20
neurodevelopmental disorders, cannabidiol, CBDV, translational models, clinical trials	P489
Neuroendocrine	P736
neuroendocrinology	37.3
neuroepigenetics	P674
neurofunctional domains	P332
Neuroimage	11.5
neuroimaging	31.3, P96, P555, P558, P583, P741
Neuroimaging Analysis	P200, 20.4
neuroimmune	P565, P343
neuroimmune activation	P725
Neuroimmune communication	49, 49.1
neuroimmune mechanisms	P142, P147, P368
Neuro-immune regulatory System (NIREGS)	28, 28.5
neuroinflammation	17.3, P456, 15.2, 30.1, P128, P253, P269, P401, P566, P765
neuroinformatics	P34, P181
Neurokinin	3.2
Neurological and Psychiatric Disorders	P595, P656
neuromelanin	P541
Neuromelanin-sensitive MRI	P492, P522, P541, P774, P784
Neurometabolism	55.5
Neuromodulation	6, 6.3, 38, 55, 21.2, P329, P568, P578, P586, P593
neuromodulators	P473
Neuronal ensembles	P387, P475, P621, P667, P830, 6.5
Neuronal excitability	32.3
Neuronal Oscillations	P254, P573
neuron-derived extracellular vesicles	P95, P507
neuropathic pain	P41, P611, P612
neuropeptides	P74, P391, P510, P712, P827
neuropharmacology	P626, P677
Neuropharmacology	P606, P611
Neuroplasticity	37.3, P626, P238, P594, P658, P675
neuroplastogen	P231, P627, P692, 31.2
Neuropsychiatric Disorders	P136, P726, 18.2
Neuropsychiatric Disorders [Schizophrenia, Parkinson's Disease, Major Depressive Disorder]	31.5
neuropsychiatric indications	P429
neuropsychiatric symptoms	37
Neuropsychiatric symptoms (NPS)	P486
neuroscience	16
Neurosteroid	P242, P257, P696
Neurostimulation	P573, P587
neurosurgery	5.2
neuroticism	P234, P555
Neurotoxicants	P604
neurotranscriptomics	P346, P614
Neurotransmitter release	P144, P737
Neurotrophins	P829
Neurovascular	P191
Neurovasculature	P26
new intervention targets	P529
NF-kappaB	P103
nicotinamide riboside	P161
nicotine	11.3, P344, P513
nicotine addiction	P70, P306
nicotine dependence	P592
Nicotine exposure	P349
nicotinic acetylcholine receptor	35.5
nicotinic acetylcholine receptors	P372
nightmares	P689
Nitazene	P628
Nitrous Oxide	P157
NMDA Antagonists	P201
NMDA glutamate receptors	P601, P619
NMDA Receptor	P560
Nociceptin/orphanin FQ	P727
noncoding RNA	36.2
Non-hallucinogenic	P627
Nonhuman Primate Models	P399
Nonhuman Primates	P140
non-human primates	P377, P556, P558
Non-invasive Neuromodulation	P32, P235, P316, P457, P682, 45.3
Non-opioid, Non-addictive Therapeutics	P371
Non-Pharmacological Therapy	P864
Non-Suicidal Self-injury (NSSI)	P6, P416, P545
non-suicidal self-injury disorder	P541
norepinephrine	13, 13.5, P478, P615, P707, P464
Normative Modeling	39.2, P525, P597, P796
Nos1	21.1
novel methods	P558
Novel Rapid Antidepressant	P201
Novel Targets	P105, P588
novel therapy	42
Novel treatment	25
Npas4	P145, P146, P387
NR2B NAM	P250
NREM sleep	21, 21.3, 55.5, P262, P770
nT2*	P171
Nucleus accumbens	4.4, P461, 3.2, 6.5, 18, 18.2, 18.3, 29.4, 50.1, P364, P836, P423, P138, P272, P390, P395, P406, P467, P473, P618, P817, P830
nucleus accumbens (NAA)	P350
nucleus accumbens core	P366
Nucleus Accumbens Shell	8.3

- nutrition P509
 Obesity 22.2, P517, P600
 Obesity and eating disorders 30.4
 Obsessive Compulsive Disorder 44.4, P445, P519, P630, P632
 obsessive-compulsive disorder P633
 Obsessive-Compulsive Disorder (OCD) P157, P579, P631, P634
 Obsessive-Compulsive Disorder (OCD) P635
 Obsessive-compulsive personality traits P55
 obstructive sleep apnea P770
 Olfaction 49.1, 49.3
 olfactory 49, 49.2
 Olfactory epithelium 49.3
 oligodendrocytes P51, P134, P137, P437
 Open Chromatin Regions 53.4
 Open Label Trials P314
 open science P546
 Operant behavior P468
 opiate P367
 Opioid 10.3, P28, P291, P373
 Opioid abuse P317, P371, P385
 opioid addiction 11.4, 18, 26, 26.3, 35, 50.1, P98, P292, P338, P350, P356, P362, P602, P647, P732
 Opioid agonist treatment 26
 Opioid craving P307, 43.4
 opioid dependence P177, P375, P397
 opioid dependence, pharmacotherapy, animal model, withdrawal 8.3, P139, P371
 Opioid Mortality 44.5
 opioid overdose 23.4
 Opioid peptides 35.3
 opioid sparing P613
 Opioid system P540, 34
 opioid tolerance P67, P621
 Opioid treatment P299
 opioid use disorder 18.3, 23.2, 26.2, 26.4, 35.2, 26.5, P404, P304, P312, P176, P290, P307, P316, P320, P364, P376, P378, P407, P436, P609, P722
 opioid withdrawal P67, P139, P316, P397
 opioids 43.2, P343, P608, P377
 Opioid-sparing effects P371
 OPRM1 gene 35.2
 optical biosensors P389
 optogenetics 19.4, P735
 orbital frontal cortex P396, P840
 Orbitofrontal P829
 orbitofrontal cortex 30.1, P388, P409
 orexin receptor 2 agonist P274
 orexin/hypocretin 30.2, 30.3, P274, P820
 organic cation transporter 3 P711
 Organoids 46.4
 orphan receptors P605
 OUD P551
 Outbred mice P374
 outcome controllability 57.4
 ovarian hormones 11.3, 4.1, P867, P714
 overeating 30.3
 oxycodone 1.1, 1.2, P284, P347
 oxytocin P347, P512, P823, P827
 P3b P778
 PACAP 42.4, P371, P704, P712
 Pachyman P143
 Pain 5, 5.4, 43, 5.5, P71, P288, P291, P307, P334, P369, P641, P645, P697
 pain analgesia P416, P455
 Pain sensitivity P462
 Pancreatic Euglycemic Clamp P598
 panic disorder P401
 panss P767, P872
 parabrachial nucleus P397, P712
 parahippocampal gyrus 17.2
 paraventricular nucleus of the hypothalamus 29.3, P837, P838
 paraventricular nucleus of the thalamus 3, P459
 Parent - child dyads P317, P685
 Parental Factors P49, P57
 parenting distress P21
 Parkinson's disease P652
 Partial agonist Ligands P610
 parvalbumin P844
 Parvalbumin fast-spiking GABAergic interneurons P466
 parvalbumin interneurons P452
 parvalbumin interneurons/perineuronal nets P386
 Parvalbumin neurons P130
 passive sensing 14, 14.3, 44, 44.2
 pathophysiology 25
 Patient outcomes 16
 Patient Reported Outcomes P162, P750
 Patient Selection P247, P230
 patient-centricity P782
 pattern separation P25, P178
 Pavlovian conditioning P467
 PBMC P98
 pediatric P427
 Pediatric anxiety disorders P53
 Peer Stress P218
 Perceived stress 36.5, P656, P833
 periaqueductal grey (PAG) P381, P460
 Perimenopausal Depression P193
 Perinatal development P821
 Peripheral-Central Nervous System Interface 49
 persistent avoidance P206, P363
 personalized medicine 25.4, P56, P590
 PET P10, P637
 PET imaging 5.5, 26.5, 5, 15, 15.1, 27.4, P747, P16, P236, P243, P631, P649, P784, P850
 PET Imaging Study P52, P509, P679
 phantom pain P653
 Pharmacodynamics 45.5, P654
 Pharmacoepidemiology P430
 pharmacogenomics P213, P444
 pharmacokinetic P367
 Pharmacokinetics 10.5, P208, P213, P654, P767
 Pharmacologic augmentation P800
 Pharmacology 20.5, P500, P813
 pharmacotherapy P158, P818
 Pharmacovigilance P430
 Phase 1 P155
 phase 1 study P159
 Phase 2 P692
 Phase II clinical trial P601, P802
 Phosphodiesterase-4 (PDE4) 45.5
 Phosphodiesterase-4B (PDE4B) P402, P620
 phosphorylated IRS1 P507
 phosphorylation 21.4
 Photometry P468
 physical activity P203
 Physical exercise P496
 Pilot Study P598
 PKA 21.4
 Placebo Effect P455
 Placebo effects 5.4
 Placebo Response P44
 placebo-controlled trial P802
 placenta P503, P564, P835
 placenta stem cell models P132
 Placental Inflammation P84
 plasticity 31.3, P272

Platelet derived growth factor	P383	Prenatal immune exposures	15.3, 29.2
pleiotropy analysis	P442	prenatal stress	P835
Polydrug Use	P326	Prenatal Stress Model	42.3, P563
Polygenetic Risk Score	P115, P120, P860	Prescription Opioids	18.5, P329, P385, P641
polygenic risk scores	P646	preterm birth	P530
Polygenic scores	P745	Probabilistic learning	P448
polysomnograph	P214	probabilistic reversal learning	P75, P448, P737
polysubstance use	P319, P324, P351, P399	Procyanidin	P80
pooled	P244, P245	Progesterone	P866
Population Assessment	P432	Pro-inflammatory cytokines	P717
Population Health	P553	Prolonged Exposure Therapy	P152, P701
Population neuroscience	P493	Propofol	P262
Positive Affect Treatment	P56	Prospect theory	P13
positive allosteric modulators	P159	protective factors	P514
positive mood	47.3	Proteomics	36, 36.5, 46.4, P104, P131, P144, P481, P666
positron emission tomography	P633, P402	proton magnetic resonance spectroscopy	P713, P863, P241
Positron Emission Tomography (PET) Imaging	26, 26.2, 26.3, P523, P528, P556, P557, P763, P771	Prucalopride	P64
Post Traumatic Stress Disorder	39.5, P681, P689, P691	Psilocin	P667
Posterior Cingulate Cortex	39.5	Psilocybin	31.4, P251, P338, P486, P635, P652, P655, P662, P663, P666, P671, P672, P676, P677, P678, P710, P653
Postmortem	P817	Psilocybin mushrooms	47.1
Postmortem Brain Tissue	P135, P305	Psilocybin therapy	31.5, P314, P660
Postmortem Brain Tissue Gene Expression	13.4, P819	Psilocybin truffles	47.1
Postmortem human brain study	P342	Psychedelic	P659
Postmortem Human Brain Tissue	P124, P128, P292, P810	psychedelic drugs	P163
Post-operative neurocognitive disorders	P438	Psychedelic effects	47.4, P656
postpartum	6.4	Psychedelic medicine	P673
Postpartum caregiving	P831	Psychedelic therapy	P653
postpartum depression	51, 51.2, 51.3, P659, P193, P713	Psychedelics	31, 45.2, 45.4, 47, P121, P195, P217, P267, P635, P650, P654, P657, P658, P661, P663, P664, P665, P666, P668, P669, P670, P671, P675, P676, P677, P693, P722
Postpartum mental health	P685	psychiatric and substance use disorders	P636
Postpartum Period	P869	Psychiatric Comorbidity	P215
post-sepsis	P566	psychiatric diagnosis	P46, P494
Postsynaptic transmission	P14	psychiatric disorders	P269, P441
posttraumatic stress	P704	psychiatric genomics	P443
Posttraumatic stress disorder (PTSD)	P360, P401, P685, P687	psychiatric illness	34
Post-traumatic stress symptoms	P683	Psychiatric Risk	7, 14.2, 4
Potential rapid anxiolytic effects.	P64	psychoactive molecule	51, 51.1, 51.2, 51.3
PPAR γ agonist	P95	psychoactive molecules	P227, P228
Prader Willi Syndrome	P489	psychological distress	44.5, P431
prairie voles	6.5	Psychological Pain	P858
pramipexole	12, 12.1, 12.2, 12.4	psychological wellbeing	P113, P553
prazosin	P557	Psychometrics	P259, P327
precision functional mapping	7.4, P536, P568	Psychoneuroimmunology	P561
precision health	16	psychopathology	P494, P22
Precision Medicine for Depression	P247	psychophysics	P602
Precision Medicine neuropsychiatric diseases	P355	psychophysiology	P415
precision psychiatry	12.3, P105, P38, P45, P100, P211, P594, P607, P630, P651	Psychoplastogens	P231, 31
Precision mental health	P105	Psychopathology	P600
Preclinical Alzheimer's Disease	37.5, P483	psychosis	P36, P481, P592, P638, P744, P759, P775, P793, P796, 49, 52, P525, P772, P783
Preclinical assessments	P376	psychosis risk	P549
Preclinical models and endpoints	42, P677, P724	psychosis spectrum disorders	P102
Pre-clinical screening	14.1	Psychosis spectrum symptoms	P10, P181, P536, P599, P760, P801, 46, 57.2
Predictive Biomarker	P44	Psychosis-Risk	P48, P793
Predictive coding	P638	Psychosocial behavior	P143
Preeclampsia	P869	psychosocial stress	P381
prefrontal cortex	P394	psychostimulants	P806, 1.1
prefrontal cortex	21.2, 29.5, 48.3, P294, P345, P350, P417, P422, P623, P847, P76, P813, P622	Psychotherapy	P43, P543
pregnancy	P418, P563, P715, P716, P869	Psychotic Disorders	P756
pregnancy/postpartum	37.3	psychotic-like experiences	P1, P7, P745, 37.2
Pregnenolone	P257	PTSD	P152, P162, P222, P310, P448, P532, P590, P627, P650, P665, P679, P682, P684, P690, P692, P693, P694, P696, P697, P698, P700, P701, P702, P703, P705, P706, P715, 4.3, 14, 14.1, 39, 39.4, 42.4
premenstrual dysphoric disorder	P193	Puberty	P4, P60, P443, 53.4
Prenatal	P504		
Prenatal alcohol exposure	P716		
prenatal depression	P216		
Prenatal Drug Exposure	P346		
Prenatal exposure	7.1		

public health	22.2	Reward self-administration	P721
pupil	P551	Reward sensitivity	P13
pupillometry	P72	Reward, motivation and Anhedonia	P200, P219, P718, P727, P733, 4.4
qualitative interview	P312	Reward, motivation, and anhedonia	P787, P865
qualitative research	44.4	Reward-based decision-making	P799
quality of life	P112	rhesus macaques	P400
Quality of Life (QoL)	P113	right temporo-parietal junction	P567
Quantitative Electroencephalography (qEEG)	P577	Risk and Resilience	P303, P431, P694, 48
Quetiapine	P248	Risk Calculator	P7
Rabies tracing	P676	Risk factors	P726
Racemic Ketamine and metabolites	P195	Risky decision-making	P76, 11.4
Racism and discrimination stress	P687	R-ketamine	P407, P404
raclopride	P509	RMTg	P369
Randomized Clinical Trial	P157, P158, P315, P782, P851, P447	RNA Sequencing	P15, P397
randomized controlled trial	P316	RNAscope fluorescence in situ hybridization	P357, P847
Randomized Double-Blind	P201	RNAseq	P268, P345, P373, P740
Randomized-Controlled Trial	P306, P411, P849, P854, 47.2	RNA-seq	P131, P185
Raphe-Accumbens	P69	Rodent models	P728
Rapid-Acting Antidepressant	P194	Rodents	P402
rapid-acting treatment	P162	rTMS	40.5
Rare genetic variants	P133, P446	rumination	P66
Rare genetic variation	P445	s100a10	P273
Rats	P344, P618	Safety	51.1
RCT	P508, 12.1	Safety profile	P430, P657
Real World Data	P61, P196	Safety/tolerability	47.2
real-time fMRI neurofeedback	P256, P570	SAINT	P233
real-world practice	33	salvinorin A	P710
Receptor maps	P599	schizophrenia	P174, P481, P778, P779, P782, 54
recognition memory	P683	Schizophrenia (SCZ)	17.3, 28.2, 46.4, 55, 56, P48, P85, P133, P148, P159, P441, P600, P743, P744, P751, P753, P755, P757, P773, P785, P786, P787, P788, P790, P791, P794, P800, P802, P803, P809, P810, P814, P872
Recovery	P126, P320, P412	Schizophrenia (SZ)	17, 17.2, 28.4, 54.3, P132, P187, P754, P763, P792, P795, P797, P798, P802, P808, P828
redox dysregulation	P29	schizophrenia and bipolar disorders	P102, P815
regulatory compliance	P34	schizophrenia and cognition	P806
Regulatory T cells	P783	Schizophrenia and related disorders (SRD)	P128, P515, P575, P742, P784, P804
Reinforcement learning	P349, P476, P678, P731, P761	schizophrenia negative symptoms	P811
Reinforcement-based decision-making	57.1	Schizophrenia novel treatment	P605
reinstatement	P378	Schizophrenia- Novel Treatment	P606, P763
relapse	P260, P312	Schizophrenia Spectrum Disorders	28.3, P752, P531, P789
relapse prevention	P261, P266, P803	Schizophrenia Spectrum Illness	17.3, P768
REM sleep	P238, P820	Schizophrenia subtypes	28
remission	P244, P263	Schizophrenia, Antipsychotics	P603
Renin angiotensin system	29.2	Schizophrenia, Dopamine, Antipsychotics	P607
repetitive transcranial magnetic stimulation (rTMS)	P87, P403, P577, P589, P799	Schizophrenia, negative symptoms	34.4
Replication	P53, 27.2	Schizophrenia; Functional Capacity; Antipsychotic Treatment	P806
Representational similarity analysis	P518	Seasonality	P819
reproductive transitions	37	second order conditiong	P287
resilience	P480	Sedentary Behavior	P156
Resilience to childhood maltreatment and anxiety	P23	selective attention	P861
Response inhibition	P632	Self-Administration	P335, P344, P351, P387, P450
Resting and task fMRI	20, 20.4	self-compassion	P23
Resting State Connectivity	P257, P853	self-control	P167
Resting State Functional Connectivity	P216, P226, P252, P311, P498, P533, P550, P558, P674, P689, P713, P781, P796, 7.4	Self-harm	P30
Resting-state fMRI	P515, P527, P545, 27.3	Self-medication with psychedelics	47.4
resting-state functional connectivity	P592	self-other processing	P720
Retinal imaging	P868	self-referential processing	57.2
retinoic acid	1.1	Self-titration	47.1
Rett Syndrome	P487	Semaglutide	P237, P768, 10.3
Reward	11.3, 12.2, 18.4, P11, P719, P25, P169, P298, P474, P723, P764	Semantic prediction error	P638
reward and aversion	P461	sensitization	P837
Reward Circuitry	P3, 27.2	Sensory neurobiology	P611
reward learning	P75	sensory processing	55.2
reward motivation and decision-making	11	serotonergic system	34
reward prediction error	P731		
reward processing	P23, P77		
reward response	P718		
Reward seeking	P378, P434, P725		

Serotonin	P27, P144, P234, P335, P453, P473, P562, 8, 13, 13.2	Social epidemiology	P431
Serotonin 1b receptor	P474	Social exclusion	3.4
serotonin 2A receptor	P626	Social interaction	P14
Serotonin 4 receptor	P508	Social Interactions	34.3, P823, P502, P567
Serotonin 5-HT2A Receptor	P676	social isolation stress	P469
serotonin clearance	P711	social learning	P825
serotonin receptors	P376, 8.4	social loss	P841
serotonin transporter	P711	social media	22.4
serum levels	P99	Social media language	44.5
Sex Chromosomes	53.3	Social Media Use	P280, P824, 22, 22.3
sex difference	4.3, 37.5, 53.2, 4.1, P28, P721, 11.2, 11.5, 53, 53.1, P183, P263, P270, P275, P336, P369, P379, P386, P398, P486, P499, P511, P537, P726, P729, P739, P833, P699, P853, P276, P404, P868	social neuroscience	34
Sex Hormones	11, 11.5, 53.3, P871, P73, P443, P508	social perception	57.2
sex steroid hormone receptors	53.4	Social Processing	P752, 34.3
sex-differences	P740, P741	Social reward	P730
sex-specific effects	11.4, 11, 28.2, 35, P26, P342, P349, P465	Social support	48.4
Sex-specificity	28.3	Sociocultural Factors	P327
Sexual Dimorphism	53.3, P346	Socioeconomic Status (SES)	P17
Shank3-deficient mice	P830	somatic mutation	P305
SICI	P792	Somatostatin	P422, 38.4
Simulated Driving	P301	Somatostatin-expressing interneurons	P130, P452, P466, 38.4
simulated reasoning	P46	Spatial Navigation	P454
Simulation	P266	spatial proteomics	P128
single cell omics	35, 53	spatial transcriptomics	13.4, 15, 18.2, 18.3, 35.2, 50.1, P129, 50, P483
Single nucleus RNA sequencing	35.2, 50, P124, P129, P135	Spatial working memory	P458
single nucleus RNA-seq	P809	speech processing	P638
single-cell	P185	speech production	P658
single-cell genomics	P292, P337	SPT-300	P242
Single-cell RNA sequencing	P130, P378	SSRI	P271
Single-cell transcriptomics	18.5, 53.2, P382, P810	SSRI treatment	P615
single-nucleus RNA sequencing	50.2	Stages	24
single-nucleus RNA-sequencing	P136	statistical methods	P585
Single-unit electrophysiology in vivo	P579, 43.1	Stigma	9
SLC39A8 genotype	P333	stimulant	P110
sleep	4.2, 21.2, 44.4, P282, P785, P203	stimulant use disorder	P572
sleep diary	P818	Stratification	P651
sleep disordered breathing	P816	stratified precision medicine trial	12.3
sleep disturbance	25.4, 55.2, P101, P117, P161, P246, P426, P714, 13, 13.2, 44.3, 55.5, P308	stress	P839, 29
Sleep homeostasis	21.1, 21	Stress and Trauma	P691, P694, 48.5
Sleep oscillations	45.3, 55, 55.3, 55.5, P773	Stress reactivity	P647
sleep physiology	55.2	stress resilience	P275, P845
sleep spindles	P815, 55.2	stress resilience and susceptibility	P825, 4.2
sleep-dependent learning	P770	Stress Response	3.4
slice electrophysiology	P142	stress responsivity	37.4
Slow wave activity	21.1, 21	stress vulnerability	P839
slow wave sleep	13.3	Striatal Dopamine signaling	P270, 8.2
smartphone	22, 22.1, 22.2, 22.3	striatum	8, 8.2, P476, P65, P373
smartphone apps	P280, P299, P858, 44.3	Stroke	P658
Smoking	P298	Structural MRI	P115, P261, P516, P526, P702, P745, 28.4
Smoking Cessation	P306	structural neuroimaging	P488, P530, 22.1, 46.3
SNAP25	P624	structural variants	P807
snRNASeq	P140, P708, 3.3, 3.5	Structure based design	P613
snRNA-seq	P441	subjective effects	P684, P739
sociability	P29	Substance abuse	P220
social anhedonia	P720, 44.3	Substance abuse disorders	P348, 40, 50
Social Anxiety Disorder	P52	Substance P	3.2
Social Behavior	P81, P435, P470, P473, P822, P826, P829, P830, P831, 6, 6.3, 7.2, 34.2, 34.4, 49.2	substance use	P23, P379
Social buffering	P733, P827	substance use disorder	P367, 40.5, 48.3
social cognition	P174, P295, P496, P828	Substance use disorder treatment	10.4, 40.4
Social Competence	P81	Substance Use Disorders	P118, 1, P309, P329, P384
Social defeat	3.3	Substance Use Initiation	P3, P48, P534, P539
Social defeat stress	P620	substantia nigra	P774
Social Deficits	P165, 6.2	subthalamic nucleus	P356
		Subtyping	P703
		SUD and HIV	50.2, 50.3, 50.4
		SUD risk	P327
		Suicidal behavior	P852, 23
		Suicidal ideation	P587, P852, 23, 23.2, 23.3, P850, P851, P858

Suicidality	P217, P854, P855, 28.2	TLR7	P564
Suicide	P853, 23.4, P6, P237, P860, P865	TMS	P191, P403, P567, P571, P680, P755, P792, 27.3, 40
Suicide Assessment	P857, P858	TMS targeting	P584
Suicide attempt	P649, P856, P859	TMS-EEG	40.4
Suicide ideation	P848	TNF α	P562
Suicide prediction	P212, P857, 57.3	tobacco use disorder	40.2
suicide prevention	P749, P849, P862, 57.3	tolcapone	P535
Suicide risk	P848	Tolerability	P248
Suicide risk factors	P241, P331, P749, P861	Top down regulation	P289
Sustained remission	P202	top-down control	38
Symptom dimensions	P528	Topiramate	P600
Symptom stability	P769	Touchscreen cognitive testing	P495, P673
symptom structure	32.1	Tourette syndrome	P445
Symptom Trajectories	P832	Transcend Therapeutics	P692
symptom trajectory	P639	transcranial alternating current stimulation	P289
Symptoms	P259	transcranial magnetic stimulation	P581, P583, P592
Synapse	P846, 29	transcranial magnetic stimulation (TMS)	P296, P302, P584, P585, P590, P233, P547
synapses	29.5	transcranial photobiomodulation	P527
synaptic connections	49.2	transcript isoforms	50.3
synaptic density	P771	transcription factors	P337
Synaptic Function	P10, 4	Transcriptome	P393
synaptic physiology	18.5	transcriptome biology	P199
Synaptic Plasticity	P559, P619, P676, 1, 1.1, 4.4, 31.2	Transcriptomics	P193, P350, P384, P705, P817, 18
synaptic pruning	28.5	Transdermal Estradiol	P683
Synaptic Vesicle Glycoprotein 2A (SV2A)	P528, P771	Transdiagnostic	P822, 57
Synaptogenesis	P594	Transformer	14.2
Synthetic Cannabinoids	P346	transgenerational transmission	P284
synthetic opioids	43.3	translational Alzheimer's Disease	P483
systematic review	P340, P596	Translational Animal Models	41, 42.3
systems neuroscience	P478, P665, 43.3	Translational biomarker approaches to drug development	P105, 45, 45.4
Tac2	42.4	Translational Cognitive Testing	P670, P828
Tacr1	21.1	Translational Neuroscience	P166, 33, 1, 48.3, 49
tACS	P449	translational psychiatry	P614
Tail of the Striatum	P473, 38.1	Translational research	P481, P596, 10, 42, 53
tandem repeat variation	P743	Translational studies	P75
task fMRI	P11	translocator protein (TSPO)	P850
Task-based fMRI	P147, P296, P410	TRAP2 mice	P78, P842
task-based functional connectivity	P313, P776	transcriptomic profile	P835
tau	P483, P485, 37.5	trauma	P448
TBI	31.4	Trauma exposure	P702
TCF4	P134	Traumatic Brain Injury	P39
TDCS	P165	TRD	P267
Technology	P153	treatment	P198
Teen and Young Adult	P432	Treatment Acceptability	P299
Telemedicine	P153	Treatment moderators	P197
Temporal discrimination	P109	Treatment Resistant Depression	P93, P561, P568, P675, 23.3
Teneurin-4	P501	Treatment resistant schizophrenia	P746, P751, 28.2
testosterone	P4	Treatment response	32.3
tetrahydrocannabinol	P642	Treatment transition	P769
thalamic subregional connectivity	P226	treatment-resistant depression	P260, 51, 51.1, 51.2, P83, P121, P228, P232, P241, P264, P587, P660, P217
Thalamus	P226, P681, P810	treatment-resistant Major Depressive Disorder	P223
THC	P152	treatment-resistant schizophrenia	P758, P774
theory of mind	P752, 56.3	treatment-resistant-depression	P163, P199
Therapeutic Development	P595	Treatment-Response	P529
therapeutic drug monitoring	P803	Triazole	P610
therapeutics	42.2	Tryptophan depletion	P234
theta band oscillatory measures	P116, P582, P777	TSND-201	P692
theta burst transcranial magnetic stimulation	P582	tumor necrosis factor	29.5
Theta-burst stimulation	P571, P588, 27.2	tumor necrosis factor super family	P795
Threat Conditioning	P683	twins	P282
Threat imminence continuum theory	P79	Two-photon	P389
Threat neurocircuitry	P479, P590, 38.1	ubiquitin proteasome system	P388
threat processing	P478, 38, 38.4	Ultra-processed foods	P517
Threat reactivity	6.4	Ultra-treatment resistant schizophrenia	P746
Tic disorders	P445	uncertainty	P439
time-frequency analysis	P777		
timing	54.2		
Tirzepatide	P150, 10.2		

Unsupervised Cognitive Testing	P278	Visual Processing	45.2
vagus nerve	P90	Visual threat detection	P65, P478, P586, 38.2
vagus nerve stimulation	P260, P587	VMAT2	P243, P753
valbenazine	P523, P753	VTA	19, 19.2
valence	P834, P839	Vulnerability Traits	P772
validation	P196	Wearable EEG	P773
value-based decision making	P266	wearable technology	P203, 32.2
Value-based Decision-Making	P320, P322, P729	Weight loss treatment	P323
vaping	P368	wheel running	P734
Vapor	P386	white matter	P51
variability in brain activity pattern	20.3	white-matter tract	P494
vasoactive intestinal peptide	P623	Whole exome sequencing	P446
Vasopressin 1b antagonist	P247	whole genome sequencing	P743, P766
Venlafaxine	P213	Whole-Brain Rodent Imaging	P398, P512
ventral hippocampus	6.3, P25, P62, P64, P672	Wistar Kyoto rat	P274
Ventral Pallidum	P77, P356, P730, 18, 19.2	women	P18
ventral striatum	P188	Women's Health	P866
Ventral Tegmental Area	30.3	women's health	P863
Ventral Tegmental Area	P477	Women's Mental Health	P257, P696, P716, P440
Ventral Tegmental Area (VTA)	19.4, 19.5, 30.2, P434, P451,	working memory	P522, P535, P576, P778, 37.2
.....	P513, P836	working memory fMRI	P170, P784
veterans	P585, P643, P650, P695, P853	Worry	P59, P66
VGLUT3	P69	X chromosome	P871
Vicarious defeat stress	P724	xanomeline	P156, P603, P757, P766, P767, P769, P872
violence	P30	Youth	P118, P868, P54, P119
virtual reality	P593, P695	youth and young adults	P279, P282
Visual Attention	P552	youth depression	P216, P583
visual contrast sensitivity	P756	zebrafish	P50, P500
visual cor	P689	ZIP8	P333
visual cortex	P689, P702	β-arrestin	P138
Visual plasticity	P655		